Capimune: new ciclosporin brand

Capimune is the latest brand of ciclosporin to be launched
Capimune is the latest brand of ciclosporin to be launched

Mylan has launched Capimune (ciclosporin), a new brand of ciclosporin capsules. Available in 25mg, 50mg and 100mg strengths, it is licensed for the same indications as other ciclosporin products:

  • immunosuppression in organ transplantation
  • prevention and treatment of graft-versus-host disease
  • severe active rheumatoid arthritis refractory to other agents
  • steroid-dependent or steroid-resistant nephrotic syndrome
  • severe psoriasis or severe atopic dermatitis where standard therapy is ineffective or inappropriate

Ciclosporin is a ‘critical dose’ drug: switching preparations can cause small changes in bioavailability that have significant effects on efficacy and toxicity. Consequently, the MHRA advises that patients should be stabilised on a single brand and the same brand should always be prescribed and dispensed.

View Capimune drug record

Further information: Mylan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more